

Making Cancer History®

EXPERIENCE WITH THE INTERNATIONAL BLADDER CANCER NETWORK (IBCN) & INTERNATIONAL BLADDER CANCER GROUP (IBCG)

ASHISH M. KAMAT, MD, MBBS

PROFESSOR OF UROLOGIC ONCOLOGY

WAYNE B. DUDDLESTEN PROFESSOR OF CANCER RESEARCH

PRESIDENT, INTERNATIONAL BLADDER CANCER GROUP (IBCG)

PRESIDENT, INTERNATIONAL BLADDER CANCER NETWORK (IBCN)





Mission:

- To improve the diagnosis, prevention, and treatment of **bladder cancer** through the application of **biologic markers**



Mission:

- Improve bladder cancer outcomes through **evidence-based** treatment
- Develop practical **educational tools applicable** to the global urologic community



Membership

- includes urologists, medical oncologists, radiation oncologists, statisticians, researchers with **bladder cancer expertise**
- by **application**
- **payment of dues**



Membership

- includes urologists, medical oncologists, radiation oncologists, statisticians, researchers with **bladder cancer expertise**
- by **invitation**
- **no dues**



- **US pathologists** (Cote, Cordon-Cardo, Waldman) + **urologists** (Grossman, Fradet) replied to NCI RFA on bladder marker network
- Inaugural meeting (1997) on diagnostic and prognostic markers
 - **Grant** supported (NCI)
- IBCN incorporated in **Germany** in 2006
- **Urologists** from **Europe, North America, Asia** – unmet need to address knowledge gaps in bladder cancer
- Inaugural meeting (2006) to discuss best practice **BCG** immunotherapy
 - **Industry** support (Sanofi)
- IBCG incorporated in **USA** in 2018





Current Board Members



President

Ashish M. Kamat



President

Peter J. Goebell



Secretary General

Peter Black



Secretary Adjunct Treasurer

Bernd Schmitz-Dräger



Social Media

Stephen B. Williams



Web Design

Roman Nawroth



Scientific Program Chair

Lars Dyrskjød



Treasurer-Elect


Tilman Todenhöfer



Membership



IBCN Publications



IBCN Publications



- Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, Bischoff R, Black PC, Boehm F, Céraline J, Chrousos GP, Delles C, Evenepoel P, Fridolin I, Glorieux G, van Gool AJ, Heidegger I, Ioannidis JPA, Jankowski J, Jankowski V, Jeronimo C, Kamat AM, Masereeuw R, Mayer G, Mischak H, Ortiz A, Remuzzi G, Rossing P, Schanstra JP, Schmitz-Dräger BJ, Spasovski G, Staessen JA, Stamatialis D, Stenvinkel P, Wanner C, Williams SB, Zannad F, Zoccali C, Vanholder R. Hypertension. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics? 2021 Apr;77(4):1029–1035. doi:10.1161/HYPERTENSIONAHA.120.16340. Epub 2021 Feb 15. PMID:33583200
- Wang G, Black PC, Goebell PJ, Ji L, Cordon-Cardo C, Cote R, Schmitz-Dräger BJ, Hawes D, Minner S, Sauter G, Waldman F, Groshen S, Dinney CP. Prognostic Markers in pT3 Bladder Cancer: A Study from the International Bladder Cancer Tissue Microarray Project. Urol Oncol. 2021 Feb 6:S1078–1439(21)00027–2
- Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. New horizons in bladder cancer research. Urol Oncol. 2020 Dec;38(12):867–885. doi:10.1016/j.urolonc.2018.12.014. Epub 2019 Mar 7. PMID:30852032
- Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. Editorial: Basic research in bladder cancer-refining the tools. 3rd IBCN seminars series. Urol Oncol. 2020 Dec;38(12):855–857. doi:10.1016/j.urolonc.2019.01.003. Epub 2019 Jan 23. PMID:30683454
- Benderska-Söder N, Hovanec J, Pesch B, Goebell PJ, Roghmann F, Noldus J, Rabinovic J, Wichert K, Gleichenhagen J, Käfferlein HU, Köhler CU, Johnen G, Kernig K, Hakenberg O, Jahn D, Todenhöfer T, Stenzl A, Gleissner J, Gerwert K, El-Mashtoly S, Behrens T, Brüning T, Schmitz-Dräger BJ. Towards non-invasive follow-up of low risk bladder cancer-Rationale and concept of the UroFollow trial. Urol Oncol. 2020 Dec;38(12):886–895
- Williams SB, Black PC, Dyrskjøt L, Seiler R, Schmitz-Dräger B, Nawroth R, Todenhöfer T, Kamat AM, Goebell PJ. Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. In press. <https://doi.org/10.1016/j.eururo.2019.09.006>: A Statement from the International Bladder Cancer Network. Eur Urol. 2019 Nov 28. pii: S0302-2838(19)30874-7. doi:10.1016/j.eururo.2019.11.011. [Epub ahead of print] No abstract available.
- Seiler R, Black PC, Williams SB, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series. Urol Oncol 2019 Nov;37(11):815-817. doi:10.1016/j.urolonc.2019.06.025. Epub 2019 Jul 31. Review. No abstract available.
- Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. Urol Oncol. 2018 Mar 13. pii: S1078-1439(17)30591-4. doi:10.1016/j.urolonc.2017.11.006. [Epub ahead of print]
- Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Dräger B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL. Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. Eur Urol Oncol. 2019 Mar;2(2):119-125. doi:10.1016/j.euo.2018.07.006. Epub 2018 Aug 14.
- Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. New horizons in bladder cancer research. Urol Oncol. 2019 Mar 7. pii: S1078-1439(18)30508-8. doi:10.1016/j.urolonc.2018.12.014. [Epub ahead of print] Review.
- Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. Editorial: Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series. Urol Oncol. 2019 Jan 22. pii: S1078-1439(19)30003-1. doi:10.1016/j.urolonc.2019.01.003. [Epub ahead of print] Review.
- Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21-23, 2017. Bladder Cancer. 2018 Jul 30;4(3):339-342. doi:10.3233/BLC-189032. No abstract available.
- Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. Urol Oncol. 2018 Sep;36(9):403-404. doi:10.1016/j.urolonc.2017.11.006. Epub 2018 Mar 13. No abstract available.
- Pan Q, Sathe A, Black PC, Goebell PJ, Kamat AM, Schmitz-Dräger B, Nawroth R. CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatment Strategy for Bladder Cancer. Bladder Cancer 3 (2017) 79–88
- Schmitz-Dräger C, Bonberg N, Pesch B, Todenhöfer T, Sahin S, Behrens T, Brüning T, Schmitz-Dräger BJ. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project. Urol Oncol. 2016 Oct;34(10):452-9.
- Chedgy EC, Douglas J, Wright JL, Seiler R, van Rhijn BW, Boormans J, Todenhöfer T, Dinney CP, Collins CC, Van der Heijden MS, Black PC. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. Urol Oncol. 2016 Oct;34(10):469-76.
- Vlahou A, Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Taking the next step-Advancing bladder cancer management. Urol Oncol. 2016 Oct;34(10):435-6.
- Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP,
- Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeny LA. Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. Urol Oncol. 2016 Oct;34(10):437-51.
- Kassouf W, Traboulsi SL, Schmitz-Dräger B, Palou J, Witjes JA, van Rhijn BW, Grossman HB, Kiemeny LA, Goebell PJ, Kamat AM. Follow-up in non-muscle-invasive bladder cancer—International Bladder Cancer Network recommendations. Urol Oncol. 2016 Oct;34(10):460-8.

Impact

Seminar article

Assessing the quality of studies on the diagnostic accuracy of tumor markers

Peter J. Goebell M.D.^a, A. M.D.^e, Guilherme Godoy M.D.^e, A. Knowles Ph.D.^j, Wolfgang Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer

Ashish M. Kamat M.D.^a, Ashish M. Kamat M.D.^a, Molly A. Ingersoll Ph.D.^e, Molly A. Ingersoll Ph.D.^e, Grossman M.D.^a, Thomas Sanchez-Carbayo Ph.D.ⁿ, Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project

Gang Wang M.D., Ph.D.^{a, #}, Peter C. Black M.D., F.A.C.S., F.R.C.S.C.^{b, #}, Peter J. Goebell M.D., Ph.D.^c, Lingyun Ji Ph.D.^d, Carlos Cordon-Cardo M.D., Ph.D.^e, Bernd Schmitz-Dräger M.D., Ph.D.^{c, f}, Debra Hawes M.D.^g, Bogdan Czerniak M.D., Ph.D.^h, Sarah Minner M.D.ⁱ, Guido Sauter M.D.ⁱ, Frederic Waldman M.D., Ph.D.^j, Susan Groshen Ph.D.^d, Richard J. Cote M.D.^k, Colin P. Dinney M.D.^l





INTERNATIONAL
**BLADDER CANCER
GROUP**

Founding Members



INTERNATIONAL
**BLADDER CANCER
GROUP**



Ashish Kamat, MD



Roger Buckley, MD



J Alfred Witjes, MD, PhD




Mark Soloway, MD



Marc Colombel, MD



Raj Persad, MD



Donald Lamm, MD



Joan Palou, MD, PhD




Maurizio Brausi, MD



Andreas Bohle, MD

Membership



Core Committee International Bladder Cancer Group



Health Services Research (HSR)



INTERNATIONAL
**BLADDER CANCER
GROUP**

HSR arm of the IBCG: Collaborative source for global clinicals and researchers to improve population health of bladder cancer patients.



Stephen Williams, MD, FACS
Director



Sima Porten, MD



Yair Lotan, MD



Shahrokh F. Shariat, MD



Sia Daneshmand, MD



Angela B. Smith, MD, MS



Sarah Psutka, MD, MS



Petros Grivas, MD, PhD



Hugh Mostafid, MDC, FRCS



Patrick J. Hensley, MD



Niyati Lobo, MD



Shilpa Gupta, MD

IBCG Publications



- Tan WS, et al. Intermediate-risk NMIBC: Updated Consensus Definition and Management Recommendations from the IBCG. Eur Urol Oncol. 2022
- Roumiguié M, et al. IBCG Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk NMIBC. Eur Urol. 2021.
- Matulay JT, et. Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG). BJU Int. 2020.
- Mostafid H, et al. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. Eur Urol. 2020.
- Kamat AM, et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017.
- Kamat AM, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol. 2016.
- Kamat AM, et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol 2014.
- Lamm D, et al. Defining progression in non-muscle invasive bladder cancer: it is time for a new, standard definition. J Urol 2014.
- Witjes JA, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 2013.
- Brausi M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the IBCG. J Urol 2011.
- Lamm D, et al. Maintenance bacillus Calmette-Guérin: the standard of care for the prophylaxis and management of intermediate- and high-risk non-muscle invasive bladder cancer. Eur Urol Suppl 2010.
- Colombel M, et al. Epidemiology, staging, grading and risk stratification of bladder cancer. Eur Urol Suppl 2008.
- Palou J, et al. Diagnosis of non-muscle invasive bladder cancer. Eur Urol Suppl 2008.
- Persad R, et al. Current approaches to the management of non-muscle invasive bladder cancer: comparison of current guidelines and recommendations. Eur Urol Suppl 2008.
- Lamm D, et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol Suppl 2008.
- Witjes JA, et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl 2008.

Impact



American
Urological
Association



INTERNATIONAL
**BLADDER CANCER
GROUP**

JOURNAL OF CLINICAL ONCOLOGY

REVIEW ARTICLE



Society for Immunotherapy of Cancer

Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Consensus From the International Bladder Cancer Group

EUROPEAN UROLOGY 82 (2022) 34–46

Ashish M. Kamat, Richard J. Sylvester, Andreas Böhle, Mark Soloway, Raj Persad, Roger Buckley, Marc

available at www.sciencedirect.com
journal homepage: www.europeanurology.com



European Association of Urology



Platinum Priority – Review
Editorial by Chana Weinstock

REVIEW ARTICLE | ARTICLES IN PRESS | Published: June 16, 2022

journal homepage: euoncology.europeanurology.com

International Bladder Cancer Trial Design for Patients with High-risk Non-muscle-invasive Bladder Cancer

Mathieu Roumiguié^{a,b}, Ashish M. Kamat^{a,b},
Andreas Böhle^{g,h}, Maurizio Giamberiniⁱ,
Juan Palou-Redortaⁿ, Mark Soloway^o,
Richard Sylvester^s, J. Alfred Witjes^d



European Association of Urology

Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group

Wei Shen Tan^{a,b}, Gary Steinberg^c, J. Alfred Witjes^d, Roger Li^e, Shahrokh F. Shariat^{f,g},
Morgan Roupret^h, Marko Babjukⁱ, Trinity J. Bivalacqua^j, Sarah P. Psutka^k, Stephen B. Williams^l,
Michael S. Cookson^m, Juan Palouⁿ, Ashish M. Kamat^{o,*}

BJUI
BJU International

Risk-adapted management of tumours: recommendation from the Bladder Cancer Group (IBC)


Justin T. Matulay^{*}, Mark Soloway[†], J. Alfred Witjes^d,
Donald L. Lamm^{**}, Andreas Böhle^{††}, Joan Palou^{**}, Marc Colombel^{ss},
and Ashish M. Kamat^{*}



COVID-19

Paul K. Hegde
Ashish M. Kulkarni

^a Department of Urology
School of Medicine and
Global Tuberculosis
Division of Surgery, I



(A) Map of bacillus Calmette-Guérin (BCG) vaccination policy in Europe by country. Red denotes countries without a current BCG vaccination program. Data courtesy of the BCG World Atlas ^[10]. (B) Screenshot of a heat map of COVID-19 cases in Europe from the European Centre for Disease Prevention Control website ^[8] on March 22, 2020.

The BADAS Study

www.bcgbadas.org

BCG As Defense Against SARS-CoV-2:
A Randomized Multicenter Trial

Texas

[Jeffrey Cirillo, PhD](#)

[Ashish M. Kamat, MD, MBBS](#)

[Andrew DiNardo, MD](#)

California

[Moshe Arditi, MD](#)

ClinicalTrials.gov Identifier: NCT04348370

IBCG/AUA Bladder Cancer Forum



INTERNATIONAL
**BLADDER CANCER
GROUP**



Ashish M. Kamat, MD, MBBS
Program Chair
MD Anderson Cancer Center
Houston, TX, USA



Sima Porten, MD
Program Chair
UCSF
San Francisco, CA, USA



Patrick Hensley, MD
Program Assistant
MD Anderson Cancer Center
Houston, TX, USA

Opportunities for Collaboration



INTERNATIONAL
**BLADDER CANCER
GROUP**



Annual Meetings

- Early stage researchers
- Chalk board talks – forum for exchange of ideas



Annual Meetings

- **Develop consensus guidelines**
 - Needs based (e.g. FDA)
 - Society based (e.g. SITC)

Regional Cancer Care Guidelines

- **Chilean** Bladder Cancer Guidelines (lead: **Mario Fernandez**)
- Reliance Foundation (**Mumbai**)
- **ECHO** platform (**Global**)



Collaborative Projects

- Tissue Microarray
 - P53 Tissue Microarray via MD Anderson
SPOR program
- Incubator for marker based studies



Collaborative Projects

- IBCG Registry
 - International BCG registry
- Virtual tissue based studies
 - AI based pathology assessment



INTERNATIONAL
**BLADDER CANCER
GROUP**

ASHISH M. KAMAT, MD, MBBS, FACS

akamat@mdanderson.org

 @URODOCASH

EUROPEAN
UROLOGY
ONCOLOGY